Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

LEXINGTON, Mass., April 19, 2021 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food ... Biopharmaceuticals, Oncology, FDA Curis, acute myeloid leukemia, myelodysplastic syndromes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news